Liquid biopsies may let lynch syndrome patients skip half their colonoscopies

NCT ID NCT07360834

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether annual liquid biopsies (from blood, urine, stool, and vaginal swabs) can safely replace colonoscopies every 18 months for people with Lynch syndrome. 2,000 participants will be split into two groups: one gets standard care (colonoscopy every 18 months), the other gets liquid biopsies plus a colonoscopy every 36 months. The goal is to see if the liquid biopsy approach catches cancers just as early, while being less invasive and more convenient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

liquid biopsy (blood, urine, stool, vaginal swab) and colonoscopy

What this could lead to

If successful, this could allow people with Lynch syndrome to have fewer invasive colonoscopies while still catching cancers early, improving quality of life.

What could go wrong

This is a large but early-stage study that has not yet started recruiting. Liquid biopsies may miss some early cancers, and the approach must prove it is as safe as standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis Lynch syndrome mismatch repair cancer syndrome 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Erasmus Medisch Centrum Rotterdam

    Rotterdam, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GGC Network

    Paris, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ist. Tumori di Milano

    Milan, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinicki Bolnicki Centar Sestre Milosrdnice Ustanova

    Zagreb, Croatia

    Contact Email: •••••@•••••

  • Masaryk Memorial Cancer Institute

    Brno, Czechia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Oslo University Hospital

    Oslo, Norway

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Pauls Stradins Clinical University Hospital

    Riga, Latvia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tampereen Korkeakoulusäätiö SR

    Helsinki, Finland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Edinburgh

    Edinburgh, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••